These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 32552717

  • 1. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH, Jung SS, Yeo MK, Lee DH, Yoo G, Cho SY, Oh IJ, Kim JO, Park HS, Chung C, Lee JE.
    BMC Cancer; 2020 Jun 18; 20(1):571. PubMed ID: 32552717
    [Abstract] [Full Text] [Related]

  • 2. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression.
    Lin CC, Huang YK, Cho CF, Lin YS, Lo CC, Kuo TT, Tseng GC, Cheng WC, Chang WC, Hsiao TH, Lai LC, Shih JY, Liu YH, Chao KSC, Hsu JL, Lee PC, Sun X, Hung MC, Sher YP.
    Theranostics; 2020 Jun 18; 10(24):10925-10939. PubMed ID: 33042262
    [Abstract] [Full Text] [Related]

  • 3. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D, Yoo G, Kim JO, Moon E, Huh YH, Lee SH, Jo EK, Cho SY, Lee JE, Chung C.
    Cancer Med; 2021 Feb 18; 10(4):1405-1417. PubMed ID: 33486901
    [Abstract] [Full Text] [Related]

  • 4. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, Lim DS, Choi W, Lee DH, Yoo G, Kim HB, Kang D, Moon JY, Jung SS, Kim JO, Cho SY, Park HS, Chung C.
    Biochem Biophys Res Commun; 2017 Sep 16; 491(2):493-499. PubMed ID: 28684311
    [Abstract] [Full Text] [Related]

  • 5. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Sep 16; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 6. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J, Ma Y, Bi JW, Xiong Y, Lv C, Li S, Wu N, Yang Y.
    J Exp Clin Cancer Res; 2019 Dec 04; 38(1):481. PubMed ID: 31801598
    [Abstract] [Full Text] [Related]

  • 7. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS, Li M, Xu CX, Wang D.
    Cell Death Dis; 2018 Oct 31; 9(11):1111. PubMed ID: 30382076
    [Abstract] [Full Text] [Related]

  • 8. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW, Wang YC, Wang L, Chen CY, Lee H.
    Theranostics; 2018 Oct 31; 8(5):1256-1269. PubMed ID: 29507618
    [Abstract] [Full Text] [Related]

  • 9. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L, Hou M, Liu J, Li Y, Shen W, Zhou Q.
    Zhongguo Fei Ai Za Zhi; 2022 Nov 20; 25(11):771-781. PubMed ID: 36419390
    [Abstract] [Full Text] [Related]

  • 10. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H, Okami J, Okuyama H, Nishizawa Y, Imamura F, Inoue M.
    Oncogene; 2017 May 18; 36(20):2824-2834. PubMed ID: 27893711
    [Abstract] [Full Text] [Related]

  • 11. Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
    Wang YC, Wu DW, Wu TC, Wang L, Chen CY, Lee H.
    Int J Biol Sci; 2018 May 18; 14(1):47-56. PubMed ID: 29483824
    [Abstract] [Full Text] [Related]

  • 12. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW.
    Sci Rep; 2018 Jan 10; 8(1):271. PubMed ID: 29321482
    [Abstract] [Full Text] [Related]

  • 13. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H.
    Cancer Med; 2021 Jan 10; 10(2):718-727. PubMed ID: 33305905
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
    Hong SA, Jang SH, Oh MH, Kim SJ, Kang JH, Hong SH.
    Pathol Res Pract; 2018 Mar 10; 214(3):335-342. PubMed ID: 29487002
    [Abstract] [Full Text] [Related]

  • 15. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX, Qu LY, Wen H, Zhong HS, Xu K, Qiu XS, Wang EH.
    Int J Clin Exp Pathol; 2014 Mar 10; 7(10):7304-11. PubMed ID: 25400829
    [Abstract] [Full Text] [Related]

  • 16. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y, Xu J, Zhang Y, Zhang W, Zhang X, Gu P, Zhong H, Wang H, Lu J, Han B.
    Cell Death Dis; 2021 Feb 10; 12(2):170. PubMed ID: 33568630
    [Abstract] [Full Text] [Related]

  • 17. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
    Dai C, Liu B, Li S, Hong Y, Si J, Xiong Y, Wu N, Ma Y.
    Technol Cancer Res Treat; 2021 Feb 10; 20():15330338211056809. PubMed ID: 34825849
    [Abstract] [Full Text] [Related]

  • 18. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
    Jia YL, Zhao Y, Zhen SM, Cheng ZS, Zheng BY, Liu YP, Liu LH.
    Zhonghua Zhong Liu Za Zhi; 2023 Sep 23; 45(9):779-786. PubMed ID: 37805442
    [Abstract] [Full Text] [Related]

  • 19. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.
    Int J Mol Sci; 2018 Feb 18; 19(2):. PubMed ID: 29463039
    [Abstract] [Full Text] [Related]

  • 20. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.